Nightingale Health
2,85
EUR
-0,18 %
4.590 følger denne virksomhed
HEALTH
NASDAQ Helsinki
Medical Equipment & Services
Health Care
Overview
Finansielt overblik og estimater
Investor consensus
-0,18%
-4,68%
-2,06%
-1,04%
-6,86%
+74,85%
+61,2%
-
-44,66%
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Læs mereMarkedsværdi
173,65 mio. EUR
Aktieomsætning
15,2 t EUR
P/E (adj.) (25e)
-10,63
EV/EBIT (adj.) (25e)
-6,88
P/B (25e)
2,5
EV/S (25e)
22,9
Udbytteafkast, % (25e)
-
Coverage
Head of Nordic ER Development, Analyst
Omsætning og EBIT-margin
Omsætning mio.
EBIT-% (adj.)
EPS og udbytte
EPS (adj.)
Udbytte %
Risiko
Business risk
Valuation risk
Lav
Høj
Alle
Analyse
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Conversion of Nightingale Health Plc’s Series A shares to Series B shares
Nightingale Health’s laboratory implementation in the United States progresses as planned – opens first to medical research customers in Summer 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Trading in Nightingale Health's B shares and ADRs begins on 21 March 2025 on the OTCQX International Market in the US
Nightingale Health Plc's listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will commence on 19 March 2025
Nightingale OTC trading in the US likely to start already within a week
The Finnish Financial Supervisory Authority has approved Nightingale Health Plc's Finnish prospectus
Nightingale Health establishes ADR program in the US - trading in Company's B shares and ADRs begins on 19 March 2025, at the earliest, and 24 March 2025, at the latest, on the OTCQX Market in the US
Nightingale applies for its shares to be listed on the Main Market of Nasdaq Helsinki
Nightingale Health Plc applies for its series B shares to be listed on the Main Market of Nasdaq Helsinki
Nightingale H1'FY25: Blood draws again
Nightingale, Webcast, Q2'25
Nightingale Health's half-year report: International expansion continues in Southeast Asia and the United States
